(0.17%) 5 140.25 points
(0.12%) 38 486 points
(0.25%) 17 890 points
(-0.27%) $83.62
(1.09%) $1.944
(0.30%) $2 354.20
(0.62%) $27.71
(1.71%) $937.85
(-0.17%) $0.933
(-0.32%) $10.99
(-0.28%) $0.798
(1.27%) $93.04
@ $10.36
发出时间: 15 Feb 2024 @ 04:35
回报率: -23.36%
上一信号: Feb 15 - 02:08
上一信号:
回报率: -3.09 %
Live Chart Being Loaded With Signals
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder...
Stats | |
---|---|
今日成交量 | 258 441 |
平均成交量 | 684 441 |
市值 | 491.83M |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.330 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.42 |
ATR14 | $0.0110 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Goldsmith George Jay | Sell | 23 881 | Ordinary Shares |
2024-04-16 | Goldsmith George Jay | Sell | 23 880 | Ordinary Shares |
2024-04-17 | Goldsmith George Jay | Sell | 10 850 | Ordinary Shares |
2024-04-17 | Goldsmith George Jay | Sell | 10 850 | Ordinary Shares |
2024-04-16 | Malievskaia Ekaterina | Sell | 23 881 | Ordinary Shares |
INSIDER POWER |
---|
-21.91 |
Last 98 transactions |
Buy: 820 261 | Sell: 1 253 383 |
音量 相关性
COMPASS Pathways Plc - 相关性 - 货币/商品
COMPASS Pathways Plc - 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-242 938 (0.00 %) |
EPS: | $-2.33 |
FY | 2023 |
营收: | $0 |
毛利润: | $-242 938 (0.00 %) |
EPS: | $-2.33 |
FY | 2022 |
营收: | $0 |
毛利润: | $-329 796 (0.00 %) |
EPS: | $-2.16 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.790 |
Financial Reports:
No articles found.
COMPASS Pathways Plc -
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。